Tempus AI Price Target Cut and Buy Rating Maintained by Canaccord Genuity - To The Moon

NewsNews
PostsPosts
SelectionSelection

- BarcodeBarcode
  ·01-12 12:38
  $Tempus AI(TEM)$ $JPMorgan Chase(JPM)$ $NVIDIA(NVDA)$ 🧬📊 Tempus AI $TEM Pre-JPM Shock, 83% Revenue Surge, $1.1B Contracts and 126% Retention Tempus just delivered one of the most strategically powerful pre-announcements going into JPM Healthcare in years. $TEM pre-released Q4 revenue of approximately $367M versus $360M Street, confirming upside to near-term demand while positioning the company directly in front of the global healthcare buy side. That top-line acceleration is not cosmetic. Quarterly revenue rose ~83% year-over-year, driven by expanding adoption of Tempus’ AI-powered data, applications, and oncology intelligence platform. What t
  1.27K 8
  22
  Share
  Report
- BarcodeBarcode
  ·01-12 12:38
  $Tempus AI(TEM)$ $JPMorgan Chase(JPM)$ $NVIDIA(NVDA)$ 🧬📊 Tempus AI $TEM Pre-JPM Shock, 83% Revenue Surge, $1.1B Contracts and 126% Retention Tempus just delivered one of the most strategically powerful pre-announcements going into JPM Healthcare in years. $TEM pre-released Q4 revenue of approximately $367M versus $360M Street, confirming upside to near-term demand while positioning the company directly in front of the global healthcare buy side. That top-line acceleration is not cosmetic. Quarterly revenue rose ~83% year-over-year, driven by expanding adoption of Tempus’ AI-powered data, applications, and oncology intelligence platform. What t
  1.27K 8
  22
  Share
  Report

{"themeInfo":{"themeId":"a9ece3fbec0b02bcc009fc5d47c1babf","name":"Tempus AI Price Target Cut and Buy Rating Maintained by Canaccord Genuity","description":"Canaccord Genuity has lowered the price target for Tempus AI from $95.00 to $80.00 per share while maintaining a Buy rating on the stock. This indicates a revised valuation outlook but continued positive sentiment towards the company's prospects.","image":"https://community-static.tradeup.com/news/1201dcc0482be040348fb8d4f228bb68","type":2,"style":4,"follow":false,"createTime":1766409662239,"userCounts":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/special/finance&rndata={\"themeId\":a9ece3fbec0b02bcc009fc5d47c1babf}&rnconfig={\"headerBarHidden\": true}","subscribe":false,"allowFollow":false,"hasReward":false,"rewardScore":0,"rewardValidDate":0,"rewardEnd":false,"symbols":["TEM"],"tweetCounts":1,"categoryId":"2929bb7468f5415f853fd96fb35d7c3b","options":[],"votedOptionId":"","totalUserCount":0,"followStatus":false,"themeName":"Tempus AI Price Target Cut and Buy Rating Maintained by Canaccord Genuity","tweetAmount":1,"imageIsDefault":false,"aiDerivativeIssues":[]},"tab":"essen","isFinancial":true,"allList":[{"id":520837263216984,"gmtCreate":1768192692678,"gmtModify":1768196204397,"author":{"id":"4171900329979952","authorId":"4171900329979952","name":"Barcode","avatar":"https://community-static.tradeup.com/news/6688d8fb4c2a255e3b901e79755e56df","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4171900329979952","idStr":"4171900329979952"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/S/TEM\">$Tempus AI(TEM)$</a>&nbsp;<a href=\"https://ttm.financial/S/JPM\">$JPMorgan Chase(JPM)$&nbsp;</a>&nbsp;<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA(NVDA)$&nbsp;</a> 🧬📊 Tempus AI $TEM Pre-JPM Shock, 83% Revenue Surge, $1.1B Contracts and 126% Retention Tempus just delivered one of the most strategically powerful pre-announcements going into JPM Healthcare in years. $TEM pre-released Q4 revenue of approximately $367M versus $360M Street, confirming upside to near-term demand while positioning the company directly in front of the global healthcare buy side. That top-line acceleration is not cosmetic. Quarterly revenue rose ~83% year-over-year, driven by expanding adoption of Tempus’ AI-powered data, applications, and oncology intelligence platform. What t","listText":"<a href=\"https://ttm.financial/S/TEM\">$Tempus AI(TEM)$</a>&nbsp;<a href=\"https://ttm.financial/S/JPM\">$JPMorgan Chase(JPM)$&nbsp;</a>&nbsp;<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA(NVDA)$&nbsp;</a> 🧬📊 Tempus AI $TEM Pre-JPM Shock, 83% Revenue Surge, $1.1B Contracts and 126% Retention Tempus just delivered one of the most strategically powerful pre-announcements going into JPM Healthcare in years. $TEM pre-released Q4 revenue of approximately $367M versus $360M Street, confirming upside to near-term demand while positioning the company directly in front of the global healthcare buy side. That top-line acceleration is not cosmetic. Quarterly revenue rose ~83% year-over-year, driven by expanding adoption of Tempus’ AI-powered data, applications, and oncology intelligence platform. What t","text":"$Tempus AI(TEM)$ $JPMorgan Chase(JPM)$ $NVIDIA(NVDA)$ 🧬📊 Tempus AI $TEM Pre-JPM Shock, 83% Revenue Surge, $1.1B Contracts and 126% Retention Tempus just delivered one of the most strategically powerful pre-announcements going into JPM Healthcare in years. $TEM pre-released Q4 revenue of approximately $367M versus $360M Street, confirming upside to near-term demand while positioning the company directly in front of the global healthcare buy side. That top-line acceleration is not cosmetic. Quarterly revenue rose ~83% year-over-year, driven by expanding adoption of Tempus’ AI-powered data, applications, and oncology intelligence platform. What t","images":[{"img":"https://community-static.tradeup.com/news/1d53ad285d9616ecfc3d7802cbdd4e8a","width":"1641","height":"1411"},{"img":"https://community-static.tradeup.com/news/375b0d634fec23e746326a83ee5fa436","width":"1472","height":"2042"},{"img":"https://community-static.tradeup.com/news/8fd34caa9e48550a3b543f105a1d6b77","width":"2048","height":"1118"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":22,"commentSize":8,"repostSize":39,"link":"https://ttm.financial/post/520837263216984","isVote":1,"tweetType":1,"viewCount":1266,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":3,"langContent":"EN","totalScore":0}],"essenList":[{"id":520837263216984,"gmtCreate":1768192692678,"gmtModify":1768196204397,"author":{"id":"4171900329979952","authorId":"4171900329979952","name":"Barcode","avatar":"https://community-static.tradeup.com/news/6688d8fb4c2a255e3b901e79755e56df","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4171900329979952","idStr":"4171900329979952"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/S/TEM\">$Tempus AI(TEM)$</a>&nbsp;<a href=\"https://ttm.financial/S/JPM\">$JPMorgan Chase(JPM)$&nbsp;</a>&nbsp;<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA(NVDA)$&nbsp;</a> 🧬📊 Tempus AI $TEM Pre-JPM Shock, 83% Revenue Surge, $1.1B Contracts and 126% Retention Tempus just delivered one of the most strategically powerful pre-announcements going into JPM Healthcare in years. $TEM pre-released Q4 revenue of approximately $367M versus $360M Street, confirming upside to near-term demand while positioning the company directly in front of the global healthcare buy side. That top-line acceleration is not cosmetic. Quarterly revenue rose ~83% year-over-year, driven by expanding adoption of Tempus’ AI-powered data, applications, and oncology intelligence platform. What t","listText":"<a href=\"https://ttm.financial/S/TEM\">$Tempus AI(TEM)$</a>&nbsp;<a href=\"https://ttm.financial/S/JPM\">$JPMorgan Chase(JPM)$&nbsp;</a>&nbsp;<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA(NVDA)$&nbsp;</a> 🧬📊 Tempus AI $TEM Pre-JPM Shock, 83% Revenue Surge, $1.1B Contracts and 126% Retention Tempus just delivered one of the most strategically powerful pre-announcements going into JPM Healthcare in years. $TEM pre-released Q4 revenue of approximately $367M versus $360M Street, confirming upside to near-term demand while positioning the company directly in front of the global healthcare buy side. That top-line acceleration is not cosmetic. Quarterly revenue rose ~83% year-over-year, driven by expanding adoption of Tempus’ AI-powered data, applications, and oncology intelligence platform. What t","text":"$Tempus AI(TEM)$ $JPMorgan Chase(JPM)$ $NVIDIA(NVDA)$ 🧬📊 Tempus AI $TEM Pre-JPM Shock, 83% Revenue Surge, $1.1B Contracts and 126% Retention Tempus just delivered one of the most strategically powerful pre-announcements going into JPM Healthcare in years. $TEM pre-released Q4 revenue of approximately $367M versus $360M Street, confirming upside to near-term demand while positioning the company directly in front of the global healthcare buy side. That top-line acceleration is not cosmetic. Quarterly revenue rose ~83% year-over-year, driven by expanding adoption of Tempus’ AI-powered data, applications, and oncology intelligence platform. What t","images":[{"img":"https://community-static.tradeup.com/news/1d53ad285d9616ecfc3d7802cbdd4e8a","width":"1641","height":"1411"},{"img":"https://community-static.tradeup.com/news/375b0d634fec23e746326a83ee5fa436","width":"1472","height":"2042"},{"img":"https://community-static.tradeup.com/news/8fd34caa9e48550a3b543f105a1d6b77","width":"2048","height":"1118"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":22,"commentSize":8,"repostSize":39,"link":"https://ttm.financial/post/520837263216984","isVote":1,"tweetType":1,"viewCount":1266,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":3,"langContent":"EN","totalScore":0}],"allBottom":false,"essenBottom":false}